Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

So on that note, Ypsomed Holding (VTX:YPSN) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit ...

So on that note, Ypsomed Holding (VTX:YPSN) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a ...

0.13 = CHF87m ÷ (CHF1.2b - CHF513m) (Based on the trailing twelve months to September 2024). So, Ypsomed Holding has an ROCE of 13%. That's a pretty standard return and it's in line with the industry ...

0543 ET – Novo Nordisk has no choice but to perform with its CagriSema drug, to show that it is still leading the obesity space, Stifel analyst Eric Le Berrigaud writes. The competition made ...

The company expects late-stage data for CagriSema, due to be published next month, to show that the drug cuts weight by 25% in just over a year. That compares with up to 16% from Novo Nordisk’s ...